ECSP045044A - Un procedimiento para reducir la mortalidad y morbilidad asociadas a enfermedades criticas - Google Patents

Un procedimiento para reducir la mortalidad y morbilidad asociadas a enfermedades criticas

Info

Publication number
ECSP045044A
ECSP045044A EC2004005044A ECSP045044A ECSP045044A EC SP045044 A ECSP045044 A EC SP045044A EC 2004005044 A EC2004005044 A EC 2004005044A EC SP045044 A ECSP045044 A EC SP045044A EC SP045044 A ECSP045044 A EC SP045044A
Authority
EC
Ecuador
Prior art keywords
procedure
reduce mortality
critical diseases
morbility
diseases
Prior art date
Application number
EC2004005044A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of ECSP045044A publication Critical patent/ECSP045044A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención describe el uso de compuestos peptídicos del tipo glucagón (GLP-1) para reducir la mortalidad y morbilidad asociada a enfermedades críticas donde el paciente está predispuesto a/o sufre algún tipo de insuficiencia respiratoria.
EC2004005044A 2001-10-01 2004-04-01 Un procedimiento para reducir la mortalidad y morbilidad asociadas a enfermedades criticas ECSP045044A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32633001P 2001-10-01 2001-10-01

Publications (1)

Publication Number Publication Date
ECSP045044A true ECSP045044A (es) 2004-04-28

Family

ID=23271764

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005044A ECSP045044A (es) 2001-10-01 2004-04-01 Un procedimiento para reducir la mortalidad y morbilidad asociadas a enfermedades criticas

Country Status (19)

Country Link
US (2) US20040235726A1 (es)
EP (1) EP1443952A4 (es)
JP (1) JP2005523877A (es)
KR (1) KR20040040482A (es)
CN (1) CN1561224A (es)
BR (1) BR0212620A (es)
CA (1) CA2462543A1 (es)
CZ (1) CZ2004441A3 (es)
EA (1) EA200400501A1 (es)
EC (1) ECSP045044A (es)
HR (1) HRP20040258A2 (es)
HU (1) HUP0600437A2 (es)
IL (1) IL160631A0 (es)
MX (1) MXPA04002996A (es)
NO (1) NO20041351L (es)
PL (1) PL373846A1 (es)
SK (1) SK1432004A3 (es)
WO (1) WO2003028626A2 (es)
ZA (1) ZA200402557B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003532691A (ja) 2000-05-05 2003-11-05 ノボ ノルディスク アクティーゼルスカブ 重症疾患神経障害
WO2003066084A1 (en) * 2002-02-07 2003-08-14 Novo Nordisk A/S Use of glp-1 compound for treatment of critically ill patients
US20030199445A1 (en) 2002-02-07 2003-10-23 Knudsen Lotte Bjerre Use of GLP-1 compound for treatment of critically ill patients
DE60335608D1 (de) * 2002-02-27 2011-02-17 Pharmain Corp Zusammensetzungen zur abgabe von therapeutika und anderen materialien und verfahren zu ihrer herstellung und verwendung
US7635463B2 (en) 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
JP2007536214A (ja) 2003-12-16 2007-12-13 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス Ｇｌｐ−１類似体
WO2005112977A2 (en) * 2004-04-23 2005-12-01 Pharmain, Ltd. Compositions for treatment with glucagon-like peptide, and methods of making and using the same
CN101258163B (zh) 2005-06-30 2013-08-21 益普生制药股份有限公司 Glp-1药物组合物
KR101529318B1 (ko) 2005-12-19 2015-06-16 파마인 코포레이션 치료제를 전달하기 위한 소수성 코어 담체 조성물, 이조성물의 제조 방법 및 그 조성물의 이용 방법
JP2009534423A (ja) 2006-04-20 2009-09-24 アムジェン インコーポレイテッド Ｇｌｐ−１化合物
JP2010043001A (ja) * 2006-11-09 2010-02-25 Sanwa Kagaku Kenkyusho Co Ltd Ｇｌｐ−１誘導体とその用途
US7960336B2 (en) 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
US20090176892A1 (en) 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
ES2561208T3 (es) 2008-09-12 2016-02-25 Novo Nordisk A/S Método de acilación de un péptido o una proteína
US8889618B2 (en) 2008-11-07 2014-11-18 The General Hospital Corporation C-terminal fragments of glucagon-like peptide-1 (GLP-1)
EP2216042A1 (en) 2009-02-09 2010-08-11 Ipsen Pharma S.A.S. GLP-1 analogues pharmaceutical compositions
DE102009024229B3 (de) * 2009-06-08 2010-10-14 Salzsieder, Eckhard, Dipl.-Phys., Dr. rer.nat. Indikationseinrichtung zur automatisierten Bestimmung des individuellen Inkretin-Sensitivitäts-Indexes eines Probanden
JP2013530993A (ja) 2010-07-02 2013-08-01 アンジオケム インコーポレーテッド 治療用コンジュゲートのための短く且つｄ−アミノ酸を含有するポリペプチドおよびその使用
WO2012061466A2 (en) 2010-11-02 2012-05-10 The General Hospital Corporation Methods for treating steatotic disease
WO2013006692A2 (en) 2011-07-06 2013-01-10 The General Hospital Corporation Methods of treatment using a pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1)
US9452225B2 (en) * 2012-03-01 2016-09-27 Novo Nordisk A/S GLP-1 prodrugs
WO2021222535A1 (en) * 2020-05-01 2021-11-04 Irazu Bio Method for treating respiratory viral infections comprising administration of fatty acid compositions
CN116847868A (zh) * 2021-01-29 2023-10-03 韩美药品株式会社 用于预防或治疗肺部疾病的包括gip衍生物或其长效共轭物的药学组合物
CN118344462B (zh) * 2024-06-18 2024-11-08 苏州易合医药有限公司 一种用于肺部给药的索马鲁肽突变体、融合蛋白及相关产品

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US6006753A (en) * 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
MY155270A (en) * 1998-09-24 2015-09-30 Lilly Co Eli Use of glp-1 or analogs in treatment of stroke
US6271241B1 (en) * 1999-04-02 2001-08-07 Neurogen Corporation Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors

Also Published As

Publication number Publication date
NO20041351L (no) 2004-06-30
CN1561224A (zh) 2005-01-05
JP2005523877A (ja) 2005-08-11
NO20041351D0 (no) 2004-03-31
WO2003028626A2 (en) 2003-04-10
PL373846A1 (en) 2005-09-19
SK1432004A3 (sk) 2005-03-04
MXPA04002996A (es) 2004-07-15
EP1443952A2 (en) 2004-08-11
HUP0600437A2 (en) 2006-09-28
EP1443952A4 (en) 2005-09-07
US20080032932A1 (en) 2008-02-07
CZ2004441A3 (cs) 2004-11-10
CA2462543A1 (en) 2003-04-10
EA200400501A1 (ru) 2005-06-30
US20040235726A1 (en) 2004-11-25
WO2003028626A3 (en) 2003-10-09
ZA200402557B (en) 2005-05-09
KR20040040482A (ko) 2004-05-12
HRP20040258A2 (en) 2004-12-31
BR0212620A (pt) 2005-09-20
IL160631A0 (en) 2004-07-25

Similar Documents

Publication Publication Date Title
ECSP045044A (es) Un procedimiento para reducir la mortalidad y morbilidad asociadas a enfermedades criticas
PY0314531A (es) Preparaciones acidas de insulina con estabilidad mejorada
WO2003058203A3 (en) Extended glucagon-like peptide-1 analogs
HRP20020996B1 (hr) Analozi peptida-1 nalik na glukagon
ECSP034811A (es) Derivados heterocicliloxi-, -tioxi - y - aminobenzazole tales como ligandos 5-hidroxitriptamina-6
AR053495A1 (es) Moduladores del peptido 1 similar al glucagon humano y su uso en el tratamiento de la diabetes y condiciones relacionadas
ES2159184T3 (es) Nueva posologia para la dmni.
BR0115055A (pt) Terapia de combinação compreendendo agentes anticonvulsantes e antidiabéticos
ATE394423T1 (de) Analoge des glucagon ähnlichen peptides-1 (glp-1)
ECSP045474A (es) 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de 5-hidroxitriptamina-6
ECSP055774A (es) Nuevo medicamento para el tratamiento de la enfermedad pulmonar obstructiva crónica
ATE193541T1 (de) Insulinotropes hormon
ECSP024346A (es) Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
ES2196006T3 (es) Procedimiento y sistema para producir oxido nitrico mezclado con aire u otros gases para su uso en medicina.
DE69327309D1 (de) Verwendung eines peptids
UY27244A1 (es) Uso del acido- (4´-trifluormetilfenil) - amida (z) -2- ciano-3- hidroxi-but-2-enoico para el tratamiento de la esclerosis multiple
ATE536881T1 (de) Glp-1, exendin-4, peptid-analoga und verwendungen davon
PA8561901A1 (es) Cis-imidazolinas
GT200300142A (es) Agonistas del receptor (vpac2) del peptido activante de la adenilato ciclasa hipofisaria (pacap) y sus metodos de uso farmacologicos
IL172396A0 (en) Replikin peptides and uses thereof
PA8587801A1 (es) Isomeros posicionales de interferon alfa 2-a monopegilado
AR002949A1 (es) Análogos del peptido p277 y composiciónes farmaceuticas y preparaciónes que los comprenden para el tratamiento o diagnostico de diabetes y un equipo para diagnosticar.
CR7285A (es) Un procedimiento para reducir la mortalidad y morbilidad asociadas a enfermedades criticas
BR0316810A (pt) Uso de um agonista de ppar(alfa) e metformina para diminuir os triglicerìdeos séricos
BRPI0520080A2 (pt) capacete de mergulho transparente